Gilead Sciences’ Hepatitis C Drug Candidate May Have First Mover Advantage
Posted on August 08, 2012 at 15:17 PM EDT
Biopharmaceutical company Gilead Sciences’ (Nasdaq: GILD) GS-7977 is moving to Phase III study for treating patients with Hepatitis C and is likely to have a lead over others in market entry. The latest prediction is that its peers may have a minimum one year to take on the company’s next generation candidate in developing drugs for Hepatitis C treatment. [More...]
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here